Search results
Nature's answer to JAK3 inhibition: Discovering five herbal and natural alternatives
The Gainesville Sun via Yahoo News· 7 months agoJAK3 inhibitors have become a buzzword in pharmaceuticals, with significant implications for...
Pfizer (PFE) to Report Q2 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 11 months agoHigher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like...
My Top Value Stock to Buy In 2023
Motley Fool· 1 year agoThe past three years have been significant for pharma giant Pfizer (NYSE: PFE) and its shareholders. For instance, Pfizer's shares remain reasonably...
The Top Healthcare Stock to Buy With $100
Motley Fool· 2 years agoOne of the great things about investing in stocks is that you don't need millions of dollars in the bank to get started. Let's look at an incredible...
Pfizer's (PFE) Etrasimod Filings Receive Review Acceptance
Zacks via Yahoo Finance· 2 years agoThe regulatory filings seek approval for Pfizer's (PFE) etrasimod in UC indication. A final decision...
Here's Why Pfizer's High-Yield Dividend Could Be Even Safer Than You Might Think
Motley Fool· 10 months agoPfizer (NYSE: PFE) reported a 53% year-over-year decline in revenue in its latest quarter. There's...
Pfizer's (PFE) Q3 Loss Narrows, Sales Miss on COVID Slump
Zacks via Yahoo Finance· 8 months agoPfizer PFE reported third-quarter 2023 adjusted loss per share of 17 cents, which was narrower than...
Pfizer's (PFE) Key Drugs to Drive Q3 Earnings Amid COVID Decline?
Zacks via Yahoo Finance· 8 months agoPfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter,...
Pfizer's (PFE) Q2 Earnings Beat, Sales Miss, Stock Declines
Zacks via Yahoo Finance· 11 months agoPfizer (PFE) beats estimates for second-quarter earnings but misses the same for sales. It trims the...
2 Pandemic Stocks That Could Make You Richer in 2023 and Beyond
Motley Fool· 2 years agoTwo examples are Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). Pfizer has been one of the most...